Status:
UNKNOWN
A Dosing Study of Hyperbaric Oxygen Therapy (HBOT) on Epigenetic Aging
Lead Sponsor:
TruDiagnostic
Conditions:
Aging
Eligibility:
All Genders
40-70 years
Phase:
PHASE2
PHASE3
Brief Summary
This study aims to assess the impact of hyperbaric oxygen therapy on a number of outcomes, including epigenetic aging, inflammation, and cellular health.
Detailed Description
While current research has identified many mechanisms of action, effects and cell signaling benefits resulting from HBOT, we do not have a firm understanding of the timeframe and dosage for many of th...
Eligibility Criteria
Inclusion
- Any sex, gender orientation, and ethnicity
- Between ages 40 and 70
- Must be willing and able to participate in venipuncture, health history and clinical assessments, lab test assessment, hyperbaric oxygen treatment.
- Participants must also agree to maintain their current lifestyle choices consistent with pre- participation with this study. Participants should not change their exercise programs, diets, sleep patterns supplements or other. Any significant changes in their lifestyle choices must be reported to the staff.
Exclusion
- Significant change in diagnosis and/or treatment of major illness or injury within 2 years prior to screening, e.g., diabetes, cancer, cardiovascular disease, psychiatric condition
- Any ongoing immune system concerns or immunodeficiency disease
- Body mass index (BMI) changes of more than 5% over the course of the study
- Changes in weight of more than 15 lbs. during the course of the study
- Presence of a severe active infection as determined by the principal investigator.
- Any other illness, disorder, alcohol or chemical dependence that in the opinion of investigators would render study participation unsuitable
- Unable or unwilling to provide required biological sample
- Unable or unwilling to avoid pregnancy during study period
- Presence of cataracts before the study begins
- Myopic changes within the first 30 days of treatment
Key Trial Info
Start Date :
March 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT05297019
Start Date
March 1 2022
End Date
July 1 2023
Last Update
April 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New Jersey HBOT
Florham Park, New Jersey, United States, 07932